Celairis Therapeutics has secured exclusive rights to commercialise Ocugen's investigational gene therapy for retinitis pigmentosa in Australia, New Zealand and the member states of the Association of ...

The Therapeutic Goods Administration has completed its inspection of Q-Gen Cell Therapeutics, the Brisbane contract manufacturer that will make Miro Sciences' StemSmart stem cell product for a planned ...

Brandon Capital is inviting biotechnology, healthcare and life sciences businesses to take up office space alongside it at 31 ...

Nexsen says it aims to file its RenalSure bedside test for acute kidney injury with the US Food and Drug Administration in ...

CLINUVEL managing director Philippe Wolgen has rejected calls from some shareholders for a share buyback. At the company's ...

Tetratherix has reworked its royalty arrangements with the University of Sydney, replacing a layered set of payment ...

Melbourne biotechnology company Cartherics will use London Life Sciences Week to seek international partners, collaborators, and investors as its lead ovarian cancer therapy moves toward its first ...

AVITA Medical has raised its full-year revenue guidance and removed the going concern qualification from its accounts after a ...

NuNerve is taking its lead motor neurone disease therapy into a national Phase 2 trial after early signs of disease stabilisation and functional improvement in its first human study.

Miro Sciences, formerly NeuroScientific Biopharmaceuticals, has announced that it plans to start a randomised Phase 2 trial ...

Radiopharm Theranostics has reached agreement with the US Food and Drug Administration on the design of a single pivotal ...